1. Immunology/Inflammation
  2. CD3
  3. Flotetuzumab

Flotetuzumab  (Synonyms: MGD006; S80880)

Cat. No.: HY-P99623 Purity: 98.71%
SDS COA

Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML).

For research use only. We do not sell to patients.

CAS No. : 1664355-28-5

Size Price Stock Quantity
1 mg USD 750 In-stock
5 mg USD 1950 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML)[1][2].

Isotype

V-lambda-VH _ V-kappa-VH'

Species

Humanized

IC50 & Target

CD123, CD3[1]

In Vitro

Flotetuzumab (0.01 ng/mL, 0.1 ng/mL; 144 h) increases IFN-γ, IL-10, and IL-6 secretion in primary PBMCs[1].
Flotetuzumab (10-6-102 ng/mL; 24 h) shows cytotoxicity against the Kasumi-3 AML cell line using human PBMCs or cynomolgus[1].
Flotetuzumab (0.01 ng/mL, 0.1 ng/mL; 6 d) dose-dependently inhibits leukemic blasts growth[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Primary PBMCs
Concentration: 0.01 ng/mL, 0.1 ng/mL
Incubation Time: 6 days
Result: Resulted in a dose-dependent depletion of leukemic blasts, accompanied by a concomitant expansion of autologous T cells, up-regulation of the proliferation marker Ki-67, and a proportionally greater expansion of CD8+ cells.
In Vivo

Flotetuzumab (0.5-4 μg/kg; intraperitoneal implantation; continuous infusion for 6 d) shows antitumor activity in human peripheral blood mononuclear cells (PBMCs)-reconstituted tumor-bearing mice[1].
Flotetuzumab (0.5 mg/kg; once every 5 d; for 30 d) improves mouse survival and induces T-cell proliferation in mouse NTPL-146 patient-derived xenograft (PDX) model of acute myeloid leukemia (AML)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: PBMCs-reconstituted tumor model: NSG/β2m-/- mice intradermally implanted with the KG-1a (AML-M0) cells on day 0 and intraperitoneally injected with human PBMCs on day 1[1]
Dosage: 0.5 μg/kg, 1 μg/kg, and 4 μg/kg;
Administration: Peritoneally implantation with mini-osmotic pumps; continuous infusion from days 16 to 22;
Result: Inhibited tumor volume significantly.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Flotetuzumab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • V-Lambda-VH_V-Kappa-VH'
Biological Activity
  • Immobilized Flotetuzumab can bind Human IL-3R alpha/CD123 Protein (hFc Tag). The EC50 for this effect is 3.75 ng/mL.
  • Immobilized Flotetuzumab can bind Human CD3 epsilon/CD3e Protein (ECD, hFc Tag). The EC50 for this effect is 1.33 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Flotetuzumab
Cat. No.:
HY-P99623
Quantity:
MCE Japan Authorized Agent: